Iovance Biotherapeutics Stock Today
| IOVA Stock | USD 3.54 0.02 0.56% |
PerformanceVery Weak
| Odds Of DistressLow
|
Iovance Biotherapeutics is trading at 3.54 as of the 22nd of March 2025, a 0.56 percent decrease since the beginning of the trading day. The stock's open price was 3.56. Iovance Biotherapeutics has less than a 14 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of October 2010 | Category Healthcare | Classification Health Care |
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patients immune system to eradicate cancer cells. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. The company has 327.88 M outstanding shares of which 63.6 M shares are currently shorted by private and institutional investors with about 6.16 trading days to cover. More on Iovance Biotherapeutics
Moving together with Iovance Stock
Moving against Iovance Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Iovance Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Cancer Fighters (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsIovance Biotherapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Iovance Biotherapeutics' financial leverage. It provides some insight into what part of Iovance Biotherapeutics' total assets is financed by creditors.
| |||||
Iovance Biotherapeutics (IOVA) is traded on NASDAQ Exchange in USA. It is located in 825 Industrial Road, San Carlos, CA, United States, 94070 and employs 838 people. Iovance Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.16 B. Iovance Biotherapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 327.88 M outstanding shares of which 63.6 M shares are currently shorted by private and institutional investors with about 6.16 trading days to cover.
Iovance Biotherapeutics currently holds about 424.46 M in cash with (352.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69.
Check Iovance Biotherapeutics Probability Of Bankruptcy
Ownership AllocationIovance Biotherapeutics has a total of 327.88 Million outstanding shares. The majority of Iovance Biotherapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Iovance Biotherapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Iovance Biotherapeutics. Please pay attention to any change in the institutional holdings of Iovance Biotherapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Iovance Ownership Details
Iovance Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Artisan Partners Limited Partnership | 2024-12-31 | 4.5 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 4.1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 4 M | |
| Principal Financial Group Inc | 2024-12-31 | 3.6 M | |
| Venbio Select Advisor Llc | 2024-12-31 | 3.5 M | |
| Palo Alto Investors, Llc | 2024-12-31 | 3 M | |
| Balyasny Asset Management Llc | 2024-12-31 | 2.8 M | |
| Ubs Group Ag | 2024-12-31 | 2.7 M | |
| Mpm Oncology Impact Management Lp | 2024-12-31 | 2.7 M | |
| Vanguard Group Inc | 2024-12-31 | 27.5 M | |
| Mhr Fund Management Llc | 2024-12-31 | 24.4 M |
Iovance Biotherapeutics Historical Income Statement
Iovance Stock Against Markets
Iovance Biotherapeutics Corporate Management
| Friedrich MD | Chief Officer | Profile | |
| Michele PMP | Senior Management | Profile | |
| JeanMarc MBA | Chief Officer | Profile | |
| Sara Pellegrino | Senior Communications | Profile | |
| Madan Jagasia | Ex Affairs | Profile | |
| Tracy Winton | Executive Resources | Profile | |
| Brian MBA | Senior Technology | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth 151.892 | Return On Assets | Return On Equity |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.